Everyone is talking about the FDA’s proposed accelerated IND program. They are missing the startling document that spawned it.
Concurrent with the FDA announcement, HHS (FDA’s parent department) published Operation TrialBlazer, a roadmap that sets the stage for FDA’s IND changes. Its intent is extremely clear.
Start with who gets named. The roadmap discusses one competitive landscape and names exactly three countries in it. The United States. China. Australia. That is the entire map as HHS sees it.
The message: China is a threat to the US’s biotech dominance.
But Australia is not an afterthought. It is held up as the standard:
“Australia has also found success in early stage trials, being widely regarded as a top-tier country for Phase 1 clinical trials, and has one of the highest trials-per-capita rates in the world.“
Then it names the scheme directly, with Australia’s own numbers:
“Australia’s Clinical Trial Notification System allows trials to begin in fewer than 70 days after a final protocol is submitted, with regulatory approval granted in as little as 21 to 28 days and sites activated within 6 to 12 weeks.“
That speed is the advantage. It is a large part of why first-in-human is so prominent in Australia.
Again, the target of the roadmap is China. The framing is national security:
“…the United States has a critical window, measured in years, not decades, to act decisively or risk ceding military, geopolitical, and economic advantages to China.“
The numbers behind that fear are stark. China passed the US in Phase 1 share in 2021. In 2024 it registered over 7,100 trials, 39% of the global total. In 2025, global companies spent over $137 billion licensing China-based assets. The roadmap projects Chinese biotech could account for 35% of FDA approvals by 2040.
Here is the part Australia needs to sit with. China’s speed is starting to rival its own.
“China has matched [Australia’s] pace: following nationwide reforms in 2015 and September 2025 that reduced approval backlogs and increased public investments in biomedicine, respectively, their early discovery-to-IND cycles are now 50% to 70% faster than the rest of the world.“
The US knows exactly where it loses. The roadmap admits its own bottleneck in the same breath as the comparison:
“In the U.S., IND applications go into effect after 30 days from receipt by the FDA, comparable to China and Australia, but other requirements, including Institutional Review Board (IRB) approval and contract negotiation, can add up to 13 months of additional delay before a single patient is enrolled.“
So the logic is complete.
Australia built a speed advantage.
China is building theirs.
The US has now decided it has no choice but to do the same.
Speed has been Australia’s edge for years. That edge is being competed away in public, in a federal roadmap, with Australia’s own scheme cited as the thing to beat.
Fast is easy. Fast and Effective is not.
There is one key gap the Operation TrialBlazer can’t copy easily. Australia’s speed is not a setting on a dial. It is the output of a system the country spent decades building.
The CTN is fast because the substantive review is genuinely distributed to Human Research Ethics Committees (HRECs), and because those committees are trusted to carry it. That trust rests on accreditation, on reliance frameworks, on reviewer competency, and on a legal culture that accepts the ethics committee as the gatekeeper. The US is not proposing that. The FDA keeps the gate. It wants CTN-class speed without CTN-style delegation, which is a much harder problem than it sounds.
Look at where the roadmap admits the delay actually lives. Not the 30-day IND clock. The 13 months of IRB approval and contract negotiation that follow. That is the periphery, and the periphery is structural and cultural. You cannot write site contracting friction out of existence in a notice. The FDA’s own pilot flags the risk it is walking into: when one institution acts as both regulatory advisor and ethics reviewer, independence is the first thing to wobble. Australia spent years getting that balance right. It does not transfer in a budget cycle.
So the threat is real, but the challenge was never just speed. The challenge is the trust infrastructure underneath the speed, and the still US has to build much of that from scratch.
That also opens a door. The IND request for information explicitly asks for help:
“Are there existing models, research networks, pilot programs, or international examples that could inform implementation?“
Australia is the obvious answer to that question. There is a constructive version of this where Australia engages rather than retreats. It could share the operational learnings of decades of notification-based review. It could push for reliance and work-sharing, so a first-in-human package generated in one jurisdiction counts toward a program in the other. It could harmonise the NAMs frameworks now, while both jurisdictions are still drafting, so the two do not end up incompatible after a decade of duplication. A faster US is only zero-sum for Australia if the two systems refuse to talk.
And Australia still holds cards the roadmap does not touch. The R&D tax incentive is not in this document, and it is not something the FDA can answer. Speed plus the offset plus quality plus proximity to Asia is a bundle, not a single lever, and the US is only reaching for one part of it.
The durable edge, though, is the one Australia is already building. Be the jurisdiction where an ethics committee can competently and quickly review a NAMs-informed, animal-reduced first-in-human package. That is the hard layer. It needs reviewer capability, not just enthusiasm, and it is exactly the work underway in the practical guidance to be published for CTN reviewers in July 2026. Speed can be copied. The competency to review modern science at speed is a genuine first-mover advantage, and it is still Australia’s to lose.
A follow-up post will break down the FDA’s actual mechanism, the Qualified Research Institution model, and why its structure changes who carries the risk.
No responses yet